Transcranial Magnetic Stimulation (TMS) for Hallucinations in Schizophrenia

This study is looking at how a non-invasive technique called Repetitive Transcranial Magnetic Stimulation (rTMS) might help us understand and potentially improve hallucinations in people with schizophrenia or schizoaffective disorder. rTMS uses a magnetic coil placed on your scalp to gently stimulate specific areas of the brain. Researchers will compare rTMS to a sham (inactive) rTMS to see if it changes brain activity related to hallucinations. You may be able to join if you are 18 to 55 years old, have schizophrenia or schizoaffective disorder, and experience auditory hallucinations. The study aims to see if rTMS can improve symptoms like hallucinations, measured by scales like the Positive and Negative Syndrome Scale (PANSS). The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 68 participants. It compares active Repetitive Transcranial Magnetic Stimulation (rTMS) to a sham (inactive) rTMS.
What's involved
You would have an initial screening, an MRI scan, five days of twice-daily rTMS sessions, and then a follow-up MRI and assessments one week after the last rTMS session.
Compensation
Not stated in the trial record.
Follow-up
You will have follow-up assessments and an MRI scan one week after your last rTMS session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05343598

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

Recruiting
NAAges 18–55InterventionalBasic science
Mclean Hospital
~68 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Repetitive Transcranial Magnetic Stimulation (rTMS)Sham Repetitive Transcranial Magnetic Stimulation (rTMS)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
functional connectivity
Measured over baseline, 1 week after TMS
+3 more outcomes measured
Schizophrenia
Schizo Affective Disorder
1 sites across 1 states
Massachusetts1
  • Mark Halko, PhD · PRINCIPAL_INVESTIGATOR · Mclean Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of schizophrenia or schizoaffective disorder

Exclusion

substance use disorder in past 3 months
ambidexterity
contraindications for TMS or MRI including :
history of neurological disorder
history of head trauma resulting in loss of consciousness
history of seizures or diagnosis of epilepsy or first degree relative family history of epilepsy
metal in brain or skull
implanted devices such as a pacemaker, medication pump, nerve stimulator or ventriculoperitoneal shunt
claustrophobic in MRI
  • functional connectivitybaseline, 1 week after TMS

    change in functional connectivity of a putative cerebellar-thalamic-cortical hallucination circuit (cerebellum to thalamus) will be assessed before and after (1 week followup) TMS stimulation.

  • Positive and Negative Syndrome Scale (PANSS)baseline

    The PANSS is clinical rating scale of symptom severity . Each descriptor is rated on a 7 point scale from 1=(absence of any symptom) to 7=(extremely severe symptoms).

  • Scale for the Assessment of Positive Symptoms (SAPS)baseline

    The SAPS is clinical rating scale of symptom severity . Each descriptor is rated on a 5 point scale from 1=(absence of any symptom) to 5=(extremely severe symptoms).

  • Auditory Hallucination Rating Scale (AHRS) Scale (AHRS)baseline

    The AHRS is a 7-item clinical rating scale used to assess auditory hallucinations.